Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Authors
Keywords
-
Journal
NEPHROLOGY
Volume 21, Issue 4, Pages 286-294
Publisher
Wiley
Online
2015-09-15
DOI
10.1111/nep.12620
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes
- (2015) S. Matthaei et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- 4B.01
- (2015) D. Cherney et al. JOURNAL OF HYPERTENSION
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet
- (2015) Tomohide Hayami et al. Journal of Diabetes Investigation
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
- (2014) Kohei Kaku et al. Cardiovascular Diabetology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Beyond Glycosuria: Exploring the intrarenal effects of SGLT-2 inhibition in diabetes
- (2014) M.C. Thomas et al. DIABETES & METABOLISM
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy
- (2014) Kento Kitada et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013
- (2014) Marie Ng et al. LANCET
- The adrenergic regulation of proximal tubular Na+/H+exchanger 3 in the rat
- (2013) V. Healy et al. Acta Physiologica
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
- (2013) Harold Bays Diabetes Therapy
- Regulation of the human Na+-dependent glucose cotransporter hSGLT2
- (2012) Chiara Ghezzi et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
- (2012) Ivan Sabolić et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
- (2011) Felix Mahfoud et al. CIRCULATION
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- The Effects of Weight LossVersusWeight Loss Maintenance on Sympathetic Nervous System Activity and Metabolic Syndrome Components
- (2010) Nora E. Straznicky et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucose-Induced Regulation of NHEs Activity and SGLTs Expression Involves the PKA Signaling Pathway
- (2010) Olívia Beloto-Silva et al. JOURNAL OF MEMBRANE BIOLOGY
- The role of the sympathetic nervous system in obesity-related hypertension
- (2009) Alexandre A. da Silva et al. CURRENT HYPERTENSION REPORTS
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
- Sympathetic nervous system behavior in human obesity
- (2008) Kevin P. Davy et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search